Business
Eton Pharmaceuticals, Inc.: We intend to seek patent protection on our internally developed products as circumstances warrant.
Revenue increased 104.9% to $80.0M, while Net income decreased 20.4% to ($4.6M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $80.0MWatch
- Profitability — Net income ($4.6M)Watch
- Cash generation — Free cash flow $10.2MOK
- Accounting — Formula distress score · no manipulation flag · earnings quality safeWatch
- Insiders — 0 buys; 2 sells in 365 daysNote
- Capital — Comparable payout data unavailableNote
Where the revenue comes from
Fiscal 2025, as Eton Pharmaceuticals, Inc. reports it. History and quarterly detail are in the app.
- Product Sales and Royalties$76.7M
- License$3.3M
Leadership changes
From Eton Pharmaceuticals, Inc.'s own filings, the day they're filed.
- Judith Matthews · President · appointmenteff. 2026-06-01
- James Gruber · Chief Financial Officer · appointmenteff. 2026-06-01
Latest filings
- 8-K · Company announcement2026-08-13
- 10-Q · Quarterly report2026-08-13
- 8-K · Company announcement2026-08-05
- 8-K · Company announcement2026-08-04
- 8-K · Company announcement2026-07-29
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Eton Pharmaceuticals, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.